دورية أكاديمية
Fusarium species central nervous system infection.
| العنوان: | Fusarium species central nervous system infection. |
|---|---|
| المؤلفون: | Strong N; McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, USA., Ostrosky-Zeichner L |
| المصدر: | Current opinion in infectious diseases [Curr Opin Infect Dis] 2024 Jun 01; Vol. 37 (3), pp. 185-191. Date of Electronic Publication: 2024 Mar 18. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8809878 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-6527 (Electronic) Linking ISSN: 09517375 NLM ISO Abbreviation: Curr Opin Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Hagerstown, Md. : Lippincott Williams & Wilkins Original Publication: London, UK ; Philadelphia, PA : Gower Academic Journals, c1988- |
| مواضيع طبية MeSH: | Antifungal Agents*/therapeutic use , Fusariosis*/diagnosis , Fusariosis*/drug therapy , Fusarium*/drug effects, Humans ; Central Nervous System Fungal Infections/diagnosis ; Central Nervous System Fungal Infections/drug therapy ; Immunocompromised Host ; Incidence |
| مستخلص: | Purpose of Review: Fusarium species are an increasingly important cause of meningitis and invasive disease in immunocompromised patients as well as in otherwise healthy patients as observed in two recent healthcare-associated outbreaks. This review summarizes recently published information on treatment and diagnosis of this infection. Recent Findings: Incidence of Fusarium species meningitis and invasive fusariosis are increasing. Molecular techniques are improving the speed of diagnosis. New antifungal agents in development show good in vitro activity against some Fusarium species. New technologies, including cerebrospinal fluid (CSF) filtration, may play a role in treatment of central nervous system (CNS) disease. Due to the continued prime importance of the host immune system in recovery, immunomodulatory treatments may play a role in treatment. Summary: The overall incidence of CNS fusariosis is increasing with a continued poor prognosis, but new diagnostic and treatment modalities are in development which may offer improvements. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| References: | Matsuo T, Wurster S, Jiang Y, et al. Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes. J Antimicrob Chemother 2023; 79:297–306. Tortorano AM, Richardson M, Roilides E, et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect 2014; 20:27–46. World Health Organization, WHO. WHO fungal priority pathogens list to guide research, development and public health action. 2022. Hoenigl M, Jenks JD, Egger M, et al. Treatment of Fusarium infection of the central nervous system: a review of past cases to guide therapy for the ongoing 2023 outbreak in the United States and Mexico. Mycopathologia 2023; 188:973–981. Hoenigl M, Salmanton-Garcia J, Walsh TJ, et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infect Dis 2021; 21:e246–e257. Al-Hatmi AMS, Bonifaz A, Ranque S, et al. Current antifungal treatment of fusariosis. Int J Antimicrob Agents 2018; 51:326–332. Pagano L, Caira M, Falcucci P, Fianchi L. Fungal CNS infections in patients with hematologic malignancy. Expert Rev Anti Infect Ther 2005; 3:775–785. Nucci M, Anaissie E. Invasive fusariosis. Clin Microbiol Rev 2023; 36:e0015922. Nucci M, Nouer SA. Practical issues related to non- Aspergillus invasive mold infections. Mol Aspects Med 2023; 94:101230. Fei H, Liu X, Sun L, et al. Disseminated fusarium infection after allogeneic hematopoietic stem cell transplantation after CART: a case report. Medicine (Baltimore) 2022; 101:e31594. Peterson A, Pham MH, Lee B, et al. Intracranial fusarium fungal abscess in an immunocompetent patient: case report and review of the literature. J Neurol Surg Rep 2014; 75:e241–e245. Health MMo. Comunicado técnico semanal. Meningitis, durango 2023 [updated 11/28/2023. Available at: https://www.gob.mx/cms/uploads/attachment/file/874853/COMUNICADO_TECNICO_SEMANAL_28NOVIEMBRE2023.pdf . Valaparla VL, Banerjee P, Elnaeem A, et al. Cerebral vasospasm due to Fusarium solani meningitis: a complication from medical tourism. Case report and literature review. J Stroke Cerebrovasc Dis 2024; 33:107432. Smith DJ, Gold JAW, Chiller T, et al. Update on outbreak of fungal meningitis among US residents who received epidural anesthesia at two clinics in Matamoros, Mexico. Clin Infect Dis 2023; [Epub ahead of print]. CDC.gov. Fungal meningitis outbreak associated with procedures performed under epidural anesthesia in Matamoros, Mexico. 2023. Available at: https://www.cdc.gov/hai/outbreaks/meningitis-epidural-anesthesia.html . Tawfiq RK, Ranganath N, Lehman V, et al. Breakthrough invasive Fusarium orbital rhinosinusitis with meningitis. Mayo Clin Proc 2022; 97:1953–1955. Duong MT, Rudie JD, Mohan S. Neuroimaging patterns of intracranial infections: meningitis, cerebritis, and their complications. Neuroimaging Clin N Am 2023; 33:11–41. Alavi Darazam I, Sharifi G, Jamali E, et al. Meningoencephalitis caused by Fusarium proliferatum: an unusual case. Infection 2022; 50:1023–1027. Becerril-Gaitan A, Bindal S, Parker SL, et al. Cerebrovascular complications associated with iatrogenic fungal meningitis following surgical procedures in Mexico. Stroke 2023; 55:177–181. Nucci M, Barreiros G, Akiti T, et al. Invasive fusariosis in patients with hematologic diseases. J Fungi (Basel) 2021; 7:. Lamoth F, Lewis RE, Kontoyiannis DP. Investigational antifungal agents for invasive mycoses: a clinical perspective. Clin Infect Dis 2022; 75:534–544. Grizante Barião PH, Cayún Y, Sepúlveda M, et al. MALDI-TOF MS: A quick method to detect the susceptibility of Fusarium spp. clinical isolates to amphotericin B. Microorganisms 2023; 11:1834. Lamoth F, Nucci M, Fernandez-Cruz A, et al. Performance of the beta-glucan test for the diagnosis of invasive fusariosis and scedosporiosis: a meta-analysis. Med Mycol 2023; 61:myad061. Vadhan JD, Melo AJ, Shogan JC, et al. Fast and fusariosis: a systematic review and case report of a rapidly fatal central nervous system infection. J Emerg Crit Care Med 2022; 6:973–981. Drevinek P, Hollweck R, Lorenz MG, et al. Direct 16S/18S rRNA gene PCR followed by Sanger sequencing as a clinical diagnostic tool for detection of bacterial and fungal infections: a Systematic Review and Meta-Analysis. J Clin Microbiol 2023; 61:e0033823. Weiss ZF, Little J, Hammond S. Evolution of antifungals for invasive mold infections in immunocompromised hosts, then and now. Expert Rev Anti Infect Ther 2023; 21:535–549. Erami M, Aboutalebian S, Hashemi Hezaveh SJ, et al. Invasive Fusarium rhinosinusitis in COVID-19 patients: report of three cases with successful management. Front Cell Infect Microbiol 2023; 13:. Hoenigl M, Sprute R, Egger M, et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs 2021; 81:1703–1729. Winston DJ, Young PA, Schlamm HT, Schiller GJ. Fosmanogepix therapy of disseminated Fusarium infection. Clin Infect Dis 2023; 77:848–850. Shaw KJ, Ibrahim AS. Fosmanogepix: A review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections. J Fungi 2020; 6:239. Nau R, Blei C, Eiffert H. Intrathecal antibacterial and antifungal therapies. Clin Microbiol Rev 2020; 33:e00190-19. Risum M, Overgaard UM, Rubek N, et al. Disseminated fusariosis with cerebral involvement in a patient with acute myeloid leukemia: successful outcome with intrathecal -and systemic antifungal treatment. J Infect Chemother 2022; 28:1324–1328. Chen TK, Batra JS, Michalik DE, et al. Recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) as adjuvant therapy for invasive fungal diseases. Open Forum Infect Dis 2022; 9:ofac535. Wurster S, Watowich SS, Kontoyiannis DP. Checkpoint inhibitors as immunotherapy for fungal infections: promises, challenges, and unanswered questions. Front Immunol 2022; 13:1018202. Khatamzas E, Mellinghoff SC, Thelen M, et al. Nivolumab induces long-term remission in a patient with fusariosis. Eur J Cancer 2022; 173:91–94. Cummins DD, Morshed RA, Goldschmidt E, Kuo YH. Comparison of shunt outcomes for nonbacterial infection hydrocephalus with common hydrocephalus etiologies: a retrospective case-control study. World Neurosurg 2022; 164:e582–e589. Menendez Gonzalez M. Mechanical filtration of the cerebrospinal fluid: procedures, systems, and applications. Expert Rev Med Devices 2023; 20:199–207. |
| المشرفين على المادة: | 0 (Antifungal Agents) |
| تواريخ الأحداث: | Date Created: 20240322 Date Completed: 20240424 Latest Revision: 20240603 |
| رمز التحديث: | 20240603 |
| DOI: | 10.1097/QCO.0000000000001009 |
| PMID: | 38518108 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1473-6527 |
|---|---|
| DOI: | 10.1097/QCO.0000000000001009 |